Gene Logic to search for secondary paths for Solvay pipeline
GAITHERSBURG, Md. Gene Logic will be seeking different development paths for multiple Solvay Pharmaceutical drug candidates that were discontinued or deprioritized in clinical trials for reasons other than safety. The two companies have entered into a drug repositioning and development agreement.
As a result of the agreement, any drug candidate that Gene Logic finds a new use for may give the company an exclusive license for that drug, if Solvay chooses not to develop it. Solvay, manufacturer of Creon, would be entitled though to royalty and milestone payments if Gene Logic gets the license.
Gene Logic has said that, "its drug repositioning program seeks to find alternate development paths for drug candidates with good safety records that have been deprioritized or discontinued in clinical trials."